Vimarsana
Biggest News Aggregation in the World

Page 2 - Hal Mackins News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hal Mackins. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hal Mackins Today - Breaking & Trending Today

Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies - Vimarsana News

Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

ALAMEDA, Calif. & LUND, Sweden--(BUSINESS WIRE)--Jun 16, 2022--

Exelixis, Inc.: Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies - Vimarsana News

Exelixis, Inc.: Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

- Exelixis positioned to expand its biotherapeutics development pipeline through selection of antibody candidates directed to targets identified using BioInvent's proprietary immuno-oncology (IO) screening

Exelixis, Inc.: Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes - Vimarsana News

Exelixis, Inc.: Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform - Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics

Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline - Vimarsana News

Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Press release content from Business Wire. The AP news staff was not involved in its creation. Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline March 8, 2021 GMT ALAMEDA, Calif. & SHANGHAI--(BUSINESS WIRE)--Mar 8, 2021-- Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics (“WuXi Bio”) (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline. The agreement is the latest in a series of biologics-...

Source: apnews.com
Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer's Disease Data Presentation | Business & Finance - Vimarsana News

Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer's Disease Data Presentation | Business & Finance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 8, 2021--